Dyne Therapeutics (DYN) Operating Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Operating Expenses data on file, last reported at $125.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 2.37% year-over-year to $125.3 million in Q1 2026; TTM through Mar 2026 was $471.1 million, a 18.63% increase from a year earlier, with the FY2025 full-year figure at $468.2 million, up 36.15% from the prior year.
• Operating Expenses for Q1 2026 stood at $125.3 million, up from $116.1 million in the prior quarter.
• Over the last five years, Operating Expenses for DYN reached as high as $125.3 million in Q1 2026 and fell as low as $35.8 million in Q1 2022.
• Historically, Operating Expenses has averaged $79.4 million across 5 years, with a median of $69.2 million in 2024.
• Across the five-year window, Operating Expenses declined 22.74% in 2022 and jumped 76.95% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $40.1 million in 2022, then soared by 68.61% to $67.7 million in 2023, then soared by 43.46% to $97.1 million in 2024, then climbed by 19.59% to $116.1 million in 2025, then rose by 7.88% to $125.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $125.3 million in Q1 2026, $116.1 million in Q4 2025, and $113.9 million in Q3 2025.